In silico design of novel proton-pump inhibitors with reduced adverse effects
- 24 Downloads
The development of new proton-pump inhibitors (PPIs) with less adverse effects by lowering the pKa values of nitrogen atoms in pyrimidine rings has been previously suggested by our group. In this work, we proposed that new PPIs should have the following features: (1) number of ring II = number of ring I + 1; (2) preferably five, six, or seven-membered heteroatomic ring for stability; and (3) 1 < pKa1 < 4. Six molecular scaffolds based on the aforementioned criteria were constructed, and R groups were extracted from compounds in extensive data sources. A virtual molecule dataset was established, and the pKa values of specific atoms on the molecules in the dataset were calculated to select the molecules with required pKa values. Drug-likeness screening was further conducted to obtain the candidates that significantly reduced the adverse effects of long-term PPI use. This study provided insights and tools for designing targeted molecules in silico that are suitable for practical applications.
Keywordsproton-pump inhibitor adverse effect pharmacological mechanism toxicological mechanism pKa calculation
Unable to display preview. Download preview PDF.
This work was supported by National Natural Science Foundation of China (Nos. 31200986 and 41530105) (to RZ), Natural Science Foundation, the Shanghai Committee of Science and Technology (No. 16ZR1449800) (to RZ), the Fundamental Research Funds for the Central Universities (Nos. 10247201546 and 2000219083) (to RZ), a departmental start-up fund (to LZ), the Peter and Tommy Fund, Inc., Buffalo, NY (to LZ), Funds from the University at Buffalo Community of Excellence in Genome, Environment and Microbiome (GEM) (to LZ) and UTHealth Innovation for Cancer Prevention Research Training Program Post-doctoral Fellowship (Cancer Prevention and Research Institute of Texas, grant #RP160015) (to HK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 2.Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG, Grant AK, Shearman DJC, Whitehead R, Buckle PJ. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95(4): 903–912CrossRefGoogle Scholar
- 9.Landrum G. Rdkit: a software suite for cheminformatics, computational chemistry, and predictive modeling. 2013Google Scholar
- 13.Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014; 42(Database issue D1): D1091–D1097CrossRefGoogle Scholar
- 18.Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P, Yallou F, Bjorndahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R, Scalbert A. HMDB 3.0 — The Human Metabolome Database in 2013. Nucleic Acids Res 2013; 41(Database issue): D801–D807CrossRefGoogle Scholar
- 21.Ahmed J, Meinel T, Dunkel M, Murgueitio MS, Adams R, Blasse C, Eckert A, Preissner S, Preissner R. CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge. Nucleic Acids Res 2011; 39 (Database issue suppl_1): D960–D967CrossRefGoogle Scholar